Lys412
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.1.1
Powered by Cell Signaling Technology
Home > Ubiquitylation Site Page: > Lys412  -  FBXW7 (human)

Site Information
VWSAVTGkCLRTLVG   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 573780018

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 1 , 2 ) , mass spectrometry ( 1 , 3 ) , mutation of modification site ( 2 ) , western blotting ( 1 )
Disease tissue studied:
colorectal cancer ( 1 ) , colorectal carcinoma ( 1 ) , liver cancer ( 2 ) , hepatocellular carcinoma ( 2 )
Relevant cell line - cell type - tissue:
FHCC98 ( 2 ) , HCT116 (intestinal) ( 1 ) , HEK293T (epithelial) ( 1 , 2 ) , HepG2 (hepatic) ( 2 ) , Jurkat (T lymphocyte) ( 3 )

Upstream Regulation
Treatments:
siRNA ( 2 )

Downstream Regulation
Effects of modification on FBXW7:
molecular association, regulation ( 1 ) , protein degradation ( 1 , 2 )
Induce interaction with:
TRIP12 (human) ( 1 )

References 

1

Khan OM, et al. (2021) Proteasomal degradation of the tumour suppressor FBW7 requires branched ubiquitylation by TRIP12. Nat Commun 12, 2043
33824312   Curated Info

2

Zhang Q, et al. (2019) The MAP3K13-TRIM25-FBXW7α axis affects c-Myc protein stability and tumor development. Cell Death Differ
31186535   Curated Info

3

Udeshi ND, et al. (2013) Refined preparation and use of anti-diglycine remnant (K-ε-GG) antibody enables routine quantification of 10,000s of ubiquitination sites in single proteomics experiments. Mol Cell Proteomics 12, 825-31
23266961   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2019 Cell Signaling Technology, Inc.